EGFL7调节内皮细胞减轻小鼠异基因骨髓移植后急性GVHD
急性移植物抗宿主病(aGVHD)是异基因造血干细胞移植(allo-HSCT)后第二常见死因。基于内皮细胞功能障碍参与aGVHD且EGFL7可抑制内皮细胞活化与T细胞迁移,本研究在小鼠aGVHD模型中给予重组EGFL7(rEGFL7),发现其减轻aGVHD严重程度、改善生存且不影响移植物抗白血病效应,并提高胸腺细胞及T、B、树突状细胞计数。
要点
- rEGFL7在两种小鼠aGVHD模型中减轻aGVHD严重程度并改善生存。
- rEGFL7不影响移植物抗白血病效应。
- rEGFL7提高受体小鼠胸腺细胞及T、B、树突状细胞计数。
核心结论
- 重组EGFL7治疗可减轻小鼠异基因骨髓移植后aGVHD严重程度和死亡率,且不影响移植物抗白血病效应。
研究设计与样本
- 研究在两种小鼠aGVHD模型中给予重组EGFL7(rEGFL7)治疗,并与对照比较。
主要发现
- rEGFL7治疗降低两种小鼠aGVHD模型的aGVHD严重程度并改善受体小鼠生存。
- rEGFL7治疗不影响移植物抗白血病效应。
- rEGFL7治疗提高受体小鼠胸腺细胞、T细胞、B细胞和树突状细胞计数。
临床怎么用
- 本研究为概念验证,提示rEGFL7可能作为减轻allo-HSCT后aGVHD严重程度和死亡率的潜在策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute graft-versus-host disease (aGVHD) is the second most common cause of death after allogeneic hematopoietic stem cell transplantation (allo-HSCT), underscoring the need for novel therapies. Based on previous work that endothelial cell dysfunction is present in aGVHD and that epidermal growth factor-like domain 7 (EGFL7) plays a significant role in decreasing inflammation by repressing endothelial cell activation and T-cell migration, we hypothesized that increasing EGFL7 levels after allo-HSCT will diminish the severity of aGVHD. Here, we show that treatment with recombinant EGFL7 (rEGFL7) in 2 different murine models of aGVHD decreases aGVHD severity and improves survival in recipient mice after allogeneic transplantation with respect to controls without affecting graft-versus-leukemia effect. Furthermore, we showed that rEGFL7 treatment results in higher thymocytes, T, B, and dendritic cell counts in recipient mice after allo-HSCT. This study constitutes a proof of concept of the ability of rEGFL7 therapy to reduce GHVD severity and mortality after allo-HSCT.
引用
- Dorrance AM, Moutuou MM, Goda C, et al. Modulating endothelial cells with EGFL7 to diminish aGVHD after allogeneic bone marrow transplantation in mice. Blood Adv. 2022. PMID: 34654057. doi:10.1182/bloodadvances.2021005498
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。